WU-CART-007
- Generic Name
- WU-CART-007
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Study WU-CART-007 in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT06514794
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Phase 1
Recruiting
- Conditions
- Monomorphic Epitheliotropic Intestinal T-Cell LymphomaAnaplastic Large Cell LymphomaT-Cell Non-Hodgkin LymphomaAcute Myeloid LeukemiaT Cell Prolymphocytic LeukemiaExtranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaAdult T Cell LymphomaSezary Syndrome
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 54
- Registration Number
- NCT05377827
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04984356
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath